A detailed history of Northern Trust Corp transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 365,300 shares of VERA stock, worth $17.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
365,300
Previous 365,519 0.06%
Holding current value
$17.9 Million
Previous $13.2 Million 22.07%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$34.09 - $46.71 $7,465 - $10,229
-219 Reduced 0.06%
365,300 $16.1 Million
Q2 2024

Aug 14, 2024

SELL
$33.72 - $48.82 $233,848 - $338,566
-6,935 Reduced 1.86%
365,519 $13.2 Million
Q1 2024

May 14, 2024

BUY
$14.91 - $49.14 $754,729 - $2.49 Million
50,619 Added 15.73%
372,454 $16.1 Million
Q4 2023

Feb 13, 2024

BUY
$9.29 - $16.0 $244,614 - $421,296
26,331 Added 8.91%
321,835 $4.95 Million
Q3 2023

Nov 13, 2023

BUY
$13.71 - $19.64 $247,342 - $354,325
18,041 Added 6.5%
295,504 $4.05 Million
Q2 2023

Aug 11, 2023

BUY
$6.11 - $17.83 $513,716 - $1.5 Million
84,078 Added 43.48%
277,463 $4.45 Million
Q1 2023

May 15, 2023

BUY
$5.41 - $18.3 $367,360 - $1.24 Million
67,904 Added 54.11%
193,385 $1.5 Million
Q4 2022

Feb 13, 2023

BUY
$15.74 - $22.19 $167,017 - $235,458
10,611 Added 9.24%
125,481 $2.43 Million
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $31,848 - $53,544
2,400 Added 2.13%
114,870 $2.45 Million
Q2 2022

Aug 12, 2022

BUY
$12.82 - $23.4 $39,267 - $71,674
3,063 Added 2.8%
112,470 $1.53 Million
Q1 2022

May 13, 2022

BUY
$17.8 - $28.06 $561,661 - $885,405
31,554 Added 40.53%
109,407 $2.57 Million
Q4 2021

Feb 08, 2022

BUY
$15.01 - $35.8 $278,255 - $663,660
18,538 Added 31.25%
77,853 $2.08 Million
Q3 2021

Nov 15, 2021

BUY
$13.71 - $30.6 $813,208 - $1.82 Million
59,315 New
59,315 $1.03 Million

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.33B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.